Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$109.44M

FY 2025 · Annual

Investing Cash Flow

$94.86M

FY 2025 · Annual

Financing Cash Flow

-$2.91M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Depreciation & Amortization2.84M2.73M3.01M8.13M(950K)
Deferred Income Tax6.75M1.13M(1.29M)(6.48M)81.44M
Stock-Based Compensation15.37M16.28M14.04M12.43M9.47M
Change in Working Capital2.74M6.07M(747K)(6.56M)8.31M
Accounts Receivables(2.47M)(1.09M)(707K)(13.01M)(7.46M)
Inventory(2.23M)(4.48M)(771K)(29K)(3.47M)
Accounts Payables3.04M11.79M(10.98M)1.71M15.82M
Other Working Capital4.4M(151K)11.72M4.78M3.42M
Other Non-Cash Items3.37M(507K)(4.73M)(4.38M)12.76M
Operating Cash Flow64.21M31.98M12.8M(15.76M)(109.44M)
Capital Expenditures(552K)(679K)(383K)(490K)(998K)
Acquisitions (Net)00(100.67M)(4.23M)0
Purchases of Investments(420.46M)(349.26M)(512.61M)(364.77M)(112.38M)
Sales of Investments344.32M399.86M601.6M352.06M208.24M
Other Investing Activities00000
Investing Cash Flow(76.7M)49.93M(12.06M)(17.43M)94.86M
Debt Repayment000(155K)(1.99M)
Common Stock Issued3.55M734K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(915K)
Financing Cash Flow3.55M734K0(155K)(2.91M)
Effect of Forex Changes(85K)315K47K(163K)126K
Net Change in Cash(9.02M)82.96M792K(33.51M)(17.36M)
Free Cash Flow63.66M31.31M12.42M(16.25M)(110.44M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$220.5M
+ D&A-$950.0K
+ Stock-Based Comp$9.5M
+ Deferred Tax$81.4M
+ Working Capital$8.3M
+ Other Non-Cash$12.8M
= Operating Cash Flow-$109.4M
- Capex-$998.0K
= Free Cash Flow-$110.4M

Analysis

FY2025 free cash flow is -$110.4M. FCF conversion is 50.1% of net income. Operating cash flow was -$109.4M, with capex of -$998.0K. The largest bridge item is Deferred Tax at $81.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
10-QQuarterly reportOct 29, 2026
8-KCurrent reportOct 28, 2026

Does VNDA generate free cash flow?

Vanda Pharmaceuticals Inc. (VNDA) generated -$110.44M of free cash flow in fiscal 2025.

How much operating cash flow does VNDA produce?

Operating cash flow was -$109.44M, before capital expenditures of $998,000.00.